Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 5/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.51 |
| ▸ | RELA | Q04206 | 5/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2137399 | 0.86 | NFKB1 (0.53) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL605148 | 0.86 | NFKB1 (0.53) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL12951153 | 0.86 | NFKB1 (0.53) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL1078254 | 0.86 | NFKB1 (0.53) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL605147 | 0.86 | NFKB1 (0.53) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL5270119 | 0.86 | NFKB1 (0.53) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL605621 | 0.86 | NFKB1 (0.53) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL15215795 | 0.86 | NFKB1 (0.53) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL4951462 | 0.86 | NFKB1 (0.53) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL4274302 | 0.86 | NFKB1 (0.53) | NFKB1NFKB2RELABTKCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2834234-B1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |